Haleon (LON:HLN) Stock Gets Price Target Reduction from Berenberg Bank

Haleon (LON:HLN) had its price target decreased by Berenberg Bank from GBX 514 to GBX 365 in a research report released on Monday,Digital Look reports. Berenberg Bank currently has a buy rating on the stock.

Several other research firms have also issued reports on HLN. Royal Bank Of Canada increased their price target on shares of Haleon from GBX 370 to GBX 390 and gave the stock a “sector perform” rating in a research report on Tuesday, August 11th. Deutsche Bank Aktiengesellschaft upgraded Haleon to a “hold” rating and lowered their price objective for the company from GBX 320 to GBX 310 in a research note on Friday, October 30th. Finally, Jefferies Financial Group reissued a “buy” rating and issued a GBX 400 target price on shares of Haleon in a report on Friday, October 30th. Two investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company has an average rating of “Hold” and an average target price of GBX 356.

Haleon Price Performance

Shares of Haleon stock opened at GBX 337.60 on Monday. The company has a debt-to-equity ratio of 50.38, a quick ratio of 0.93 and a current ratio of 0.69. The firm’s 50-day simple moving average is GBX 350.65 and its 200-day simple moving average is GBX 359.86. Haleon has a twelve month low of GBX 310.50 and a twelve month high of GBX 433.60. The firm has a market cap of £29.69 billion, a P/E ratio of 18.65, a price-to-earnings-growth ratio of 1.49 and a beta of 0.24.

Haleon announced that its Board of Directors has approved a stock buyback plan on Thursday, October 29th that permits the company to buy back £500 million in outstanding shares. This repurchase authorization permits the company to repurchase up to 1.8% of its stock through open market purchases. Stock repurchase plans are generally a sign that the company’s leadership believes its stock is undervalued.

Insider Buying and Selling at Haleon

In other news, insider Blathnaid Bergin bought 7,670 shares of the company’s stock in a transaction that occurred on Friday, October 30th. The stock was acquired at an average price of GBX 324 per share, for a total transaction of £24,850.80. Insiders own 0.01% of the company’s stock.

About Haleon

Haleon (LSE / NYSE: HLN) is a world-leading consumer health company, with a clear purpose to deliver better everyday health with humanity. In July 2022, it listed as an independent company on the London and New York Stock Exchanges.

Haleon’s product portfolio spans six major categories – Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health and Therapeutic Skin Health and Other. Its long-standing brands – such as Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu and Voltaren – are built on trusted science, innovation and deep human understanding.